These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35024604)

  • 1. The effect of mAb and excipient cryoconcentration on long-term frozen storage stability - part 2: Aggregate formation and oxidation.
    Bluemel O; Buecheler JW; Hauptmann A; Hoelzl G; Bechtold-Peters K; Friess W
    Int J Pharm X; 2022 Dec; 4():100109. PubMed ID: 35024604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of mAb and excipient cryoconcentration on long-term frozen storage stability - Part 1: Higher molecular weight species and subvisible particle formation.
    Bluemel O; Anuschek M; Buecheler JW; Hoelzl G; Bechtold-Peters K; Friess W
    Int J Pharm X; 2022 Dec; 4():100108. PubMed ID: 35024603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryoconcentration and 3D Temperature Profiles During Freezing of mAb Solutions in Large-Scale PET Bottles and a Novel Scale-Down Device.
    Bluemel O; Buecheler JW; Rodrigues MA; Geraldes V; Hoelzl G; Bechtold-Peters K; Friess W
    Pharm Res; 2020 Aug; 37(9):179. PubMed ID: 32864719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of Protein Content and Number of Aggregates in Monoclonal Antibody Formulation After Large-Scale Freezing.
    Hauptmann A; Hoelzl G; Loerting T
    AAPS PharmSciTech; 2019 Jan; 20(2):72. PubMed ID: 30631964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational fluid dynamic simulations of temperature, cryoconcentration, and stress time during large-scale freezing and thawing of monoclonal antibody solutions.
    Bluemel O; Pavlišič A; Likozar B; Rodrigues MA; Geraldes V; Bechtold-Peters K; Friess W
    Eur J Pharm Biopharm; 2022 Aug; 177():107-112. PubMed ID: 35764219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Freeze concentration during freezing: How does the maximally freeze concentrated solution influence protein stability?
    Seifert I; Friess W
    Int J Pharm; 2020 Nov; 589():119810. PubMed ID: 32866649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein and solute distribution in drug substance containers during frozen storage and post-thawing: a tool to understand and define freezing-thawing parameters in biotechnology process development.
    Kolhe P; Badkar A
    Biotechnol Prog; 2011; 27(2):494-504. PubMed ID: 21302371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Method development and analysis of the water content of the maximally freeze concentrated solution suitable for protein lyophilisation.
    Seifert I; Bregolin A; Fissore D; Friess W
    Eur J Pharm Biopharm; 2020 Aug; 153():36-42. PubMed ID: 32526356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a laboratory-scale container for freezing protein solutions with detailed evaluation of a freezing process simulation.
    Roessl U; Jajcevic D; Leitgeb S; Khinast JG; Nidetzky B
    J Pharm Sci; 2014 Feb; 103(2):417-26. PubMed ID: 24338205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-Scale Freeze-Thaw of Protein Solutions: Study of the Relative Contributions of Freeze-Concentration and Ice Surface Area on Stability of Lactate Dehydrogenase.
    Minatovicz B; Sansare S; Mehta T; Bogner RH; Chaudhuri B
    J Pharm Sci; 2023 Feb; 112(2):482-491. PubMed ID: 36162492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Freeze/Thaw Process on Drug Substance Storage of Therapeutics.
    Rayfield WJ; Kandula S; Khan H; Tugcu N
    J Pharm Sci; 2017 Aug; 106(8):1944-1951. PubMed ID: 28343990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.
    Chen B; Bautista R; Yu K; Zapata GA; Mulkerrin MG; Chamow SM
    Pharm Res; 2003 Dec; 20(12):1952-60. PubMed ID: 14725359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of protein cryoconcentration and processing conditions on kinetics of dimer formation for a monoclonal antibody: A case study on bioprocessing.
    Mehta SB; Subramanian S; D'Mello R; Brisbane C; Roy S
    Biotechnol Prog; 2019 Jul; 35(4):e2836. PubMed ID: 31063635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of dextran on thermal properties, product quality attributes, and monoclonal antibody stability in freeze-dried formulations.
    Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
    Eur J Pharm Biopharm; 2020 Feb; 147():45-56. PubMed ID: 31866444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory.
    Roy ML; Pikal MJ; Rickard EC; Maloney AM
    Dev Biol Stand; 1992; 74():323-39; discussion 340. PubMed ID: 1592182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody.
    Arora J; Hickey JM; Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Weis DD; Volkin DB
    MAbs; 2015; 7(3):525-39. PubMed ID: 25875351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
    Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
    Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation.
    Kolhe P; Amend E; Singh SK
    Biotechnol Prog; 2010; 26(3):727-33. PubMed ID: 20039442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulations That Suppress Aggregation During Long-Term Storage of a Bispecific Antibody are Characterized by High Refoldability and Colloidal Stability.
    Svilenov HL; Winter G
    J Pharm Sci; 2020 Jun; 109(6):2048-2058. PubMed ID: 32194093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.